7 Hawkeye Drive
204 articles with Zevra Therapeutics
Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
Zevra Therapeutics announced that it has appointed Wendy L. Dixon, Ph.D., to the Company’s Board of Directors, effective immediately following the conclusion of the 2023 Annual Meeting of Stockholders, to fill the vacancy resulting from Dr. Travis Mickle’s resignation from the Board effective as of the day of the 2023 Annual Meeting to be held on April 25, 2023.
Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative
Zevra Therapeutics, Inc. today announced that it has joined the Sleep Data Initiative as a founding member.
Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders
Zevra Therapeutics today announced it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s 2023 Annual Meeting of Stockholders (“Annual Meeting”).
Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra,” or “the Company,” formerly “KemPharm, Inc.”), a rare disease therapeutics company, today reported its financial results for the fourth quarter and year ended December 31, 2022.
Zevra Therapeutics to Present at 35th Annual Roth Conference
Zevra Therapeutics, Inc. today announced that Richard W. Pascoe, the Company’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference on Monday, March 13, 2023, at 2:00 p.m. PT.
Zevra Therapeutics Begins Trading as ZVRA
Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol “ZVRA” on the Nasdaq Global Select Market at market open today, March 1, 2023.
Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)
Zevra Therapeutics, Inc. announced that it has become a Corporate Council member of the National Organization for Rare Disorders and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023.
Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy
Zevra Therapeutics, Inc., announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with the Company’s 2023 Annual Meeting of Stockholders, which is scheduled to take place on April 25, 2023.
Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results
Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022.
Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023
Zevra Therapeutics, Inc. today announced that arimoclomol, the Company’s orally-delivered, first-in-class investigational product candidate being developed as a treatment for Niemann-Pick disease type C (NPC), is being featured in two poster presentations during the 19th Annual WORLDSymposium™ 2023, the annual research conference dedicated to lysosomal diseases being held February 22-26, 2023 in Orlando, Florida, USA.
Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023
Zevra Therapeutics, Inc. has announced that two abstracts involving clinical research of arimoclomol for the treatment of Niemann-Pick disease type C (NPC), including advancing understanding of NPC disease progression have been accepted for poster presentations at the 19th Annual WORLD Symposium ™ 2023.
KemPharm Announces Corporate Name Change to Zevra Therapeutics
KemPharm, Inc. announced today that it changed its name to Zevra Therapeutics, Inc. (“Zevra”).
KemPharm Enhances Senior Management Team
KemPharm, Inc. announced that it has named Daniel Gallo, Ph.D., as Senior Vice President of Medical Affairs and Advocacy, and Abbi Maher, J.D., as Vice President of Legal Affairs.
KemPharm Issues Letter to Shareholders - January 24, 2023
KemPharm, Inc. today announced that Richard W. Pascoe, Chief Executive Officer of KemPharm, has issued a Letter to Shareholders.
KemPharm announced its partnership with Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
KemPharm, Inc. announced its partnership with the Hypersomnia Foundation , which engages, informs and champions the global community to improve the lives of people with idiopathic hypersomnia (IH) and related sleep disorders.
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
KemPharm, Inc. announced the promotions of Sven Guenther, Ph.D., to Chief Scientific Officer, and Christal M.M. Mickle, M.A., to Chief Product Development Officer.
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
KemPharm, Inc. announced changes to its Board of Directors and executive leadership team as part of the Company’s ongoing business transformation initiatives.
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)
KemPharm, Inc. today announced the initiation of a Phase 2 clinical trial evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder.
KemPharm Announces Appointment of Christopher Posner as New Independent Director
KemPharm, Inc. today announced the appointment of Christopher Posner to serve on the Company’s Board of Directors.
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
KemPharm, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the Orphan Drug Designation to serdexmethylphenidate (SDX), KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH), for the treatment of idiopathic hypersomnia (IH), a rare neurological sleep disorder.